Translate page

English English
en Englishbg Bulgarianzh-CN Chinese (Simplified)hr Croatiancs Czechda Danishnl Dutchfi Finnishfr Frenchde Germanel Greekiw Hebrewhi Hindiid Indonesianit Italianja Japaneseko Koreanmk Macedonianpl Polishpt Portuguesero Romanianru Russiansr Serbiansk Slovaksl Slovenianes Spanishsv Swedishth Thaitr Turkishvi Vietnamese

Meetings

ASH logoWe're bringing you highlights from the 67th ASH Annual Meeting with a summary of selected scientific sessions on CML

🌟 Oral Abstract Session: CML clinical & epidemiological - Therapeutic agents to enhance patient outcomes

Chairs: Elisabetta Abruzzese (Rome) - Vivian Oehler (Seattle)
This clinical session presented major advances in novel TKIs, frontline optimisation strategies, real-world outcomes in blast-phase CML, and next-generation approaches to achieving deeper and safer molecular responses. Across six presentations, investigators showcased: promising phase 1 data for TERN-701 and TGRX-678, updated results from a frontline asciminib combination trial, the largest US analysis of blast-phase management, a prospective study testing nilotinib vs. imatinib with early switch to improve TFR, and the first prospective trial of asciminib with dose escalation as second-line therapy. 

Collectively, the studies demonstrated:

  • High efficacy and favourable safety of new agent seven in heavily pretreated or T315I-mutated patients,
  • Asciminib’s expanding rolein both frontline combinations and second-line therapy,
  • The persistent challenge and therapeutic needs of blast-phase CML,
  • The importance of risk-adapted frontline selection to improve long-term TFR outcomes,
  • And the feasibility of dose escalation strategies with asciminib to address suboptimal responders.


Our key takeaways from the presentations:

ESHCML2026 Call for abstractsMark your calendar for the 28th ESH-iCMLf Annual
John Goldman Conference on Chronic Myeloid Leukemia: Biology and Therapy

Gothenburg (Sweden) - October 2-4, 2026
Chairs: J. Cortes, T.P. Hughes, D.S. Krause

Presentation of data at this conference will not jeopardize acceptance of the same at the following ASH congress.

Register here for the conference

Call for abstracts

Deadline for abstract submissions: May 22nd, 2026
Submit your abstract for an oral or a poster presentation

Submit your abstract here

 

ASH logoGetting ready for ASH 2025 - Plan your CML Sessions

Only a few weeks to go until the 67th Annual Meeting of the American Society of Hematology (ASH). This year, the meeting takes place in Orlando, Florida, and online from 6th-9th December. 

With a record-breaking number of abstracts submitted and more than 8,200 accepted, this premier event in hematology promises a wealth of exciting updates – including many important new insights into CML.

To help you plan your schedule, we have compiled a list of key CML sessions. These include an Education Spotlight Session, Oral Abstract Presentations, Poster sessions, and a Friday Satellite Symposium.

Don’t miss the annual iCMLf Forum and the oral presentation of the iCMLf/HARMONY Foundation CML Genomics project among this year’s highlights at ASH.

Have a question or suggestion for the iCMLf? The iCMLf’s Chief Executive, Nicola Evans will be on-site in Orlando. If you’d like to arrange a meeting, please contact us at info@cml-foundation.org.

We look forward to connecting with you at ASH 2025.

8E93043B C6B1 4819 B326 FB4CA48F4F4B Kopie 2Session Summaries from the ESH-iCMLf 27th Annual John Goldman Conference on CML: Biology and Therapy

We're bringing you highlights from the recent ESH-iCMLf 27th Annuzal John Goldman Conference on CML: Biology and Therapy with a summary of selected scientific sessions. 

🌟 Scientific Session: Stem Cells 🌟

Chair: Mary Scott (Glasgow)

This session explored new insights into leukemic stem cell biology, persistence, and the bone marrow microenvironment in CML. The speakers presented novel models and molecular mechanisms driving stem cell survival and relapse, highlighting inflammatory, metabolic, and stromal interactions shaping disease behaviour and treatment-free remission (TFR) potential.

Our key takeaways from the presentations:

Collage Fun Run photos 12025 John Goldman Fun Run -
Thank you for your support!

Thank you to everyone who joined the 2025 John Goldman Run Run, held during the recent ESH-iCMLf 27th Annual John Goldman Conference on CML: Biology and Therapy in Estoril. 

This year’s Run was a huge success!

More than 50 participants set off before sunrise for a 5-km run along the scenic seaside route, proudly wearing this year’s purple Fun Run charity t-shirts.

Together, we raised $2,900 – more funds than ever before – in support of the iCMLf programs that improve access to CML education and care in low- and middle-income countries.

A heartfelt thank you to all our individual supporters.